高危早产子痫前期孕妇24至28周停用阿司匹林:一项随机临床试验
这项多中心、开放标签、随机、3期非劣效性试验在西班牙9家产科医院纳入968名早产子痫前期高危孕妇,24至28周sFlt-1:PlGF比值≤38者随机分为24至28周停用阿司匹林组(473例)与持续至36周组(463例)。停用组早产子痫前期发生率1.48%(7/473),持续组1.73%(8/463),绝对差-0.25%(95%CI -1.86%至1.36%),达到非劣效。
要点
- 早产子痫前期高危且24至28周sFlt-1:PlGF比值≤38者,24至28周停用阿司匹林对预防早产子痫前期非劣于持续用至36周。
- 停用组早产子痫前期1.48%(7/473),持续组1.73%(8/463),绝对差-0.25%(95%CI -1.86%至1.36%)。
- 非劣效界值为两组早产子痫前期发生率差值95%CI上限小于1.9%。
核心结论
- 在早产子痫前期高危且sFlt-1:PlGF比值正常的孕妇中,24至28周停用阿司匹林对预防早产子痫前期非劣于持续用至36周。
研究设计与样本
- 多中心、开放标签、随机、3期非劣效性试验,在西班牙9家产科医院开展。
- 2019年8月20日至2021年9月15日招募968名早产子痫前期高危孕妇,936名纳入分析(干预组473例,对照组463例),随访至分娩。
主要发现
- 干预组早产子痫前期发生率为1.48%(7/473),对照组为1.73%(8/463),绝对差-0.25%(95%CI -1.86%至1.36%)。
- 两组差值95%CI上限1.36%小于预设非劣效界值1.9%,达到非劣效。
- 参与者平均(SD)年龄32.4(5.8)岁,3.4%为黑人,93%为白人。
关键数值与推荐
- 非劣效界值:两组早产子痫前期发生率差值95%CI上限小于1.9%。
- 入组条件:早产子痫前期高危且24至28周sFlt-1:PlGF比值≤38。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Aspirin reduces the incidence of preterm preeclampsia by 62% in pregnant individuals at high risk of preeclampsia. However, aspirin might be associated with an increased risk of peripartum bleeding, which could be mitigated by discontinuing aspirin before term (37 weeks of gestation) and by an accurate selection of individuals at higher risk of preeclampsia in the first trimester of pregnancy. OBJECTIVE: To determine whether aspirin discontinuation in pregnant individuals with normal soluble fms-like tyrosine kinase-1 to placental growth factor (sFlt-1:PlGF) ratio between 24 and 28 weeks of gestation was noninferior to aspirin continuation to prevent preterm preeclampsia. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, randomized, phase 3, noninferiority trial conducted in 9 maternity hospitals across Spain. Pregnant individuals (n = 968) at high risk of preeclampsia during the first-trimester screening and an sFlt-1:PlGF ratio of 38 or less at 24 to 28 weeks of gestation were recruited between August 20, 2019, and September 15, 2021; of those, 936 were analyzed (intervention: n = 473; control: n = 463). Follow-up was until delivery for all participants. INTERVENTIONS: Enrolled patients were randomly assigned in a 1:1 ratio to aspirin discontinuation (intervention group) or aspirin continuation until 36 weeks of gestation (control group). MAIN OUTCOMES AND MEASURES: Noninferiority was met if the higher 95% CI for the difference in preterm preeclampsia incidences between groups was less than 1.9%. RESULTS: Among the 936 participants, the mean (SD) age was 32.4 (5.8) years; 3.4% were Black and 93% were White. The incidence of preterm preeclampsia was 1.48% (7/473) in the intervention group and 1.73% (8/463) in the control group (absolute difference, -0.25% [95% CI, -1.86% to 1.36%]), indicating noninferiority. CONCLUSIONS AND RELEVANCE: Aspirin discontinuation at 24 to 28 weeks of gestation was noninferior to aspirin continuation for preventing preterm preeclampsia in pregnant individuals at high risk of preeclampsia and a normal sFlt-1:PlGF ratio. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03741179 and ClinicalTrialsRegister.eu Identifier: 2018-000811-26.
引用
- Mendoza M, Bonacina E, Garcia-Manau P, et al. Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. JAMA. 2023. PMID: 36809321. doi:10.1001/jama.2023.0691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。